<p>Everest Medicines Limited announced that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd., has entered into an agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. Under the agreement, Micot has granted Everest Medicines an exclusive license to commercialize MT1013 in Greater China and other Asian markets. MT1013 is described as a first-in-class dual-targeting receptor agonist polypeptide developed primarily for secondary hyperparathyroidism, with plans to expand into indications such as chronic kidney disease-mineral and bone disorder and osteoporosis. The collaboration is expected to broaden Everest Medicines’ nephrology portfolio. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260205-12015013), on February 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

<p>Everest Medicines Limited has secured an exclusive license from Shaanxi Micot Pharmaceutical Technology Co., Ltd. to commercialize MT1013 in Greater China and other Asian markets. MT1013 is a first-in-class dual-targeting receptor agonist polypeptide aimed at treating secondary hyperparathyroidism, with potential expansion into chronic kidney disease-mineral and bone disorder and osteoporosis. This collaboration will enhance Everest Medicines’ nephrology portfolio.</p>

Reuters

VanEck Biotech ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ALPS Medical Breakthrough

Tianhong CNI BIOMEDICINE ETF

Penghua CSI HK Connect Health Care Composite ETF

iShares Biotechnology ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

iShares US Pharma

Huaan Hang Seng Biotech ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

ICBCCS SSE STAR Biology and Medicine ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng Health Care ETF(QDII)

Yinhua CNI HK Connect Innovative Drugs ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Invesco Biotechnology & Genome ETF

Guotai CSI Bio-medicine ETF

SPDR S&P Biotech

Everest Medicines Secures Exclusive License to Commercialize MT1013 in Greater China and Asia